Punch Graphix
STRONG BUYPunch says its full year results will be ahead of forecasts, after a strong half-year turn in tricky markets. Spun out of Euronext-listed Punch International last year, Punch Graphix designs digital colour printers under the Xeikon brand (selling related consumables and accessories that offer a good source of recurring sales). It also develops imaging systems for off-set pre-press commercial markets.
The results to June demonstrated a 14% up tick in pre-tax profits to €13.3m (£9m), though top line growth was a more modest 7% to €84m (£56.8m). However the revenue result was good going against a record first half of ’05, and operating profits were maintained after hefty spending on sales, management and R&D. ‘We’ve shown we can make good margins, and live with the pressure in our markets’, explained new chief executive Ben van Assche, who pointed to good performances from the digital printing and pre-press businesses. He also flagged up an encouraging increase in the proportion of consumables sales, from 40% in 2005 to 44%.
Analysts at house Altium Securities view Punch as ‘significantly undervalued’ and rate the shares a strong buy on the basis of underlying market growth, top-line growth from Punch and the benefits to come from new product launches.
For the year, expect pre-tax profits to move north from £12.8m to £15.7m, delivering earnings of 10.2p and placing the shares on a budget forward p/e of 10.3. Prospective yields of 3% this year and next also underpin the investment case, as does burgeoning global use of digital printing. Erstwhile parent Punch International still controls 49%, but if you can get your hands on the shares, do so.
- Reduce text size Decrease text size
- Increase text size Increase text size
- Print article Print
- Share this article Share
- Email article to a friend Email
Market cap: £108.23m
PE Forecast: 10.3
Share price: 105.25p
Subscribe today
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
Cash Shells Directory 2010
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Coverage of AIM, techMARK and PLUS Markets
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
Take control of your investments
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
The Financial Times Guide to Personal Tax
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The AIM Guide Spring 2010
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Share recommendations and small-cap stock picks
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Popular Recommendations
Advertisement
Latest Recommendations
Delcam 01/09/2010
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Antisoma 01/09/2010
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
The Capital Pub Company 31/08/2010
London pub operator The Capital Pub Company is seeing continuing sales growth on the back of a surprisingly resilient market.
Sectors
